Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 501–600 of 1,448
Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00120 · Cited by 67
“LRP1 expression is reduced in total brain and brain capillaries with increasing age and even more reduced in AD (Kang et al., 2000; Shibata et al., 2000; Silverberg et al., 2010).”
BackgroundWhy is delirium more frequent in the elderly?
Bugiani, O. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05339-3 · Cited by 76
Jaya Prasanthi, R. P., Schommer, E., Thomasson, S., Thompson, A., Feist, G., & Ghribi, O. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.09.002 · Cited by 65
Amyloid beta accumulation in HIV‐1‐infected brain: The role of the blood brain barrier
András, I. E., & Toborek, M. (2013) · IUBMB Life · doi:10.1002/iub.1106 · Cited by 65
“LRP1 Several factors have been described as being responsible for soluble Ab removal from the brain into the circulation such as LRP1, which is expressed in blood vessels (22).”
BackgroundRoles of Extracellular Chaperones in Amyloidosis
Wyatt, A. R., Yerbury, J. J., Dabbs, R. A., & Wilson, M. R. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.004 · Cited by 75
Ketone Bodies Promote Amyloid-β1–40 Clearance in a Human in Vitro Blood–Brain Barrier Model
Versele, R., Corsi, M., Fuso, A., Sevin, E., Businaro, R., Gosselet, F., Fénart, L., & Candela, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030934 · Cited by 68
“Notably, the downregulation of LRP1 and P-gp during AD is one of the key events leading to Aβ accumulation by decreasing Aβ clearance from the brain [11,16].”
BackgroundResultReconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target
Sousa, J. A., Bernardes, C., Bernardo-Castro, S., Lino, M. M., Albino, I., Ferreira, L., Brás, J., Guerreiro, R. J., Tábuas‐Pereira, M., Baldeiras, I., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1102809 · Cited by 72
Lerose, V., Ponticelli, M., Benedetto, N., Carlucci, V., Lela, L., Tzvetkov, N. T., & Milella, L. (2024) · Plants · doi:10.3390/plants13060771 · Cited by 83
“LRP mediates the efflux of A β from the brain to the periphery [75,76].”
BackgroundZhao, Z., Li, P., Ye, S., Ning, Y., Wang, H., Peng, Y., Yang, N., Zhao, Y., Zhang, Z.-H., Chen, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02505-6 · Cited by 68
Magnesium Reduces Blood-Brain Barrier Permeability and Regulates Amyloid-β Transcytosis
Zhu, D., Su, Y., Fu, B. M., & Xu, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0896-0 · Cited by 71
“3b), comparable to in vivo measurements [20, 22].”
Lleó, A., Waldron, E., von Arnim, C. A. F., Herl, L., Tangredi, M. M., Peltan, I. D., Strickland, D. K., Koo, E. H., Hyman, B. T., Pietrzik, C. U., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413969200 · Cited by 67
Self-citationNatural antisense transcripts in diseases: From modes of action to targeted therapies
Wanowska, E., Kubiak, M. R., Rosikiewicz, W., Makałowska, I., & Szcześniak, M. W. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1461 · Cited by 72
“Among its functions, LPR1 is involved in removal of soluble β-Amyloid (Kang et al., 2000; Shibata et al., 2000).”
BackgroundCerebral Amyloid Angiopathy and Blood-Brain Barrier Dysfunction
Gireud, M., Mack, A. F., McCullough, L. D., & Urayama, A. (2020) · The Neuroscientist · doi:10.1177/1073858420954811 · Cited by 72
Yerbury, J. J., & Wilson, M. R. (2010) · Cell Stress and Chaperones · doi:10.1007/s12192-009-0122-0 · Cited by 64
“This is consistent with in vivo studies that show that the rate of clearance of Aβ from the mouse brain is significantly increased by both α2m ( Shibata et al. 2000 ) and clusterin (Bell et al. 2007).”
ResultInfluentialYuede, C. M., Lee, H., Restivo, J. L., Davis, T. A., Hettinger, J. C., Wallace, C. E., Young, K. L., Hayne, M. R., Bu, G., Li, C.-Z., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151428 · Cited by 63
Alzheimer’s Disease Risk Genes and Lipid Regulators
El Gaamouch, F., Jing, P., Xia, J., & Cai, D. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160169 · Cited by 67
3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice
Lazic, D., Sagare, A. P., Nikolakopoulou, A. M., Griffin, J. H., Vassar, R., & Zlokovic, B. V. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181035 · Cited by 65
Choroid Plexus in Alzheimer’s Disease—The Current State of Knowledge
Gião, T., Teixeira, T., Almeida, M. R., & Cardoso, I. (2022) · Biomedicines · doi:10.3390/biomedicines10020224 · Cited by 64
“BBB LRP-1 and P-gp decline with age, and notably in AD, and there is a strong negative correlation between the expression of LRP-1 on vessels and regional Aβ accumulation, implying that the presence of Aβ impacts this transporter [48,68,69].”
BackgroundQosa, H., Mohamed, L. A., Rihani, S. B. A., Batarseh, Y. S., Duong, Q.-V., Keller, J. N., & Kaddoumi, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151179 · Cited by 71
“This transport system consists of multiple receptors and transport proteins at the BBB such as the low-density lipoprotein receptor-related protein-1 (LRP1) and P-glycoprotein (P-gp) [63, 64].”
Morrone, C. D., Raghuraman, R., Hussaini, S. A., & Yu, W. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00617-4 · Cited by 69
Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.048 · Cited by 70
Qosa, H., LeVine, H., Keller, J. N., & Kaddoumi, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.029 · Cited by 60
“Trichloroacetic acid (TCA) precipitation [38] was used to measure the amount of intact and degraded (125)I-Aβ40.”
BackgroundMethodVandal, M., White, P. J., Tournissac, M., Tremblay, C., St‐Amour, I., Drouin‐Ouellet, J., Bousquet, M., Traversy, M.-T., Planel, E., Marette, A., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.024 · Cited by 69
Chernick, D., Ortiz-Valle, S., Jeong, A., Qu, W., & Li, L. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134306 · Cited by 62
Craft, D., Wein, L. M., & Selkoe, D. J. (2002) · Bulletin of Mathematical Biology · doi:10.1006/bulm.2002.0304 · Cited by 74
Yan, F., Zheng, Y., & Zhao, F. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0435-6 · Cited by 65
“Under the CHH, downregulation of LRP-1 expression might lead to a decreased transport of A across BBB from brain to bloodstream.”
InfluentialHoltzman, D. M., Bales, K. R., Paul, S. M., & Demattos, R. B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00158-8 · Cited by 71
Self-citationMerino-Zamorano, C., Fernández-de Retana, S., Montañola, A., Batlle, A., Saint-Pol, J., Mysiorek, C., Gosselet, F., Montaner, J., & Hernández-Guillamon, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150976 · Cited by 63
“The expression of beta-actin was used as a loading control for the quantification of LRP1 and LRP2 expression in the cell lysates.”
BackgroundMethodInfluentialAging alters mRNA expression of amyloid transporter genes at the blood-brain barrier
Osgood, D., Miller, M. C., Messier, A. A., Gonzalez, L., & Silverberg, G. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.011 · Cited by 63
Devraj, K., Poznanovic, S., Spahn, C., Schwall, G., Harter, P. N., Mittelbronn, M., Antoniello, K., Paganetti, P., Muhs, A., Heilemann, M., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15606463 · Cited by 63
Fujiyoshi, M., Tachikawa, M., Ohtsuki, S., Ito, S., Uchida, Y., Akanuma, S., Kamiie, J., Hashimoto, T., Hosoya, K., Iwatsubo, T., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07311.x · Cited by 58
“It was reported that brain-to-blood efflux transport of hAb(1-40) across the BBB was mediated by LRP 1 (Shibata et al. 2000), and we demonstrated that LRP1 is the receptor responsible for the hepatic uptake of hAb(1-40) (Tamaki et al.”
BackgroundInfluentialLongitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease
Rissman, R. A., Trojanowski, J. Q., Shaw, L. M., & Aisen, P. S. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0772-4 · Cited by 62
Herring, A., Lewejohann, L., Panzer, A.-L., Donath, A., Kröll, O., Sachser, N., Paulus, W., & Keyvani, K. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.007 · Cited by 72
Clusterin in Alzheimer's disease
Wu, Z., Yu, J., Li, Y., & Tan, L. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-394317-0.00011-x · Cited by 67
Bharadwaj, P., Solomon, T., Malajczuk, C. J., Mancera, R. L., Howard, M. J., Arrigan, D. W. M., Newsholme, P., & Martins, R. N. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.03.015 · Cited by 66
Effectiveness of Acupuncture for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis
Huang, Q., Luo, D., Chen, L., Liang, F.-X., & Chen, R. (2019) · Current Medical Science · doi:10.1007/s11596-019-2065-8 · Cited by 67
Vascular disorder in Alzheimer’s disease: role in pathogenesis of dementia and therapeutic targets
Zloković, B. V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00150-3 · Cited by 74
Best, J. D., Jay, M. T., Otu, F., Churcher, I., Reilly, M., Gutierrez, P. M., Pattison, C., Harrison, T., Shearman, M. S., & Atack, J. R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100271 · Cited by 63
“In addition to CSF-brain transport mechanisms, it has been demonstrated that rapid efflux of A from brain to plasma is mediated by low-density lipoprotein receptor-related protein, which also seems to be a substrate for -secretase (Shibata et al., 2000; Lleó et al., 2005).”
BackgroundMyD88 Deficiency Ameliorates β-Amyloidosis in an Animal Model of Alzheimer's Disease
Lim, J.-E., Kou, J., Song, M., Pattanayak, A., Jin, J., Lalonde, R., & Fukuchi, K.-I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.045 · Cited by 63
Mannix, R. C., Zhang, J., Park, J., Zhang, X., Bilal, K., Walker, K., Tanzi, R. E., Tesco, G., & Whalen, M. J. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.99 · Cited by 62
Poustforoosh, A., Nematollahi, M. H., Hashemipour, H., & Pardakhty, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.015 · Cited by 63
Alzheimers Disease: Pathological Mechanisms and Recent Insights
Niedowicz, D. M., Nelson, P. T., & Murphy, M. P. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376181 · Cited by 74
“exchanged across the BBB via the low-density lipoprotein receptor-related protein (LRP) on the abluminal (brain) side [50], and the receptor for advanced glycation end products (RAGE) on the luminal (blood) side [51].”
BackgroundZerbinatti, C. V., & Bu, G. (2005) · Reviews in the Neurosciences · doi:10.1515/revneuro.2005.16.2.123 · Cited by 61
Hirsch-Reinshagen, V., & Wellington, C. L. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32813aeabf · Cited by 61
The Mechanisms of Sevoflurane-Induced Neuroinflammation
Huang, X., Ying, J., Yang, D., Fang, P., Wang, X., Zhou, B., Zhang, L., Yang, F., Yu, W., Liu, X., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.717745 · Cited by 67
LRP1 modulates APP trafficking along early compartments of the secretory pathway
Waldron, E., Heilig, C., Schweitzer, A., Nadella, N., Jaeger, S., Martin, A. M., Weggen, S., Brix, K., & Pietrzik, C. U. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.006 · Cited by 60
“While both receptors exist at the blood brain barrier, RAGE binds soluble Aβ circulating in the blood and mediates its transport into the CNS via transcytosis and LRP1 governs the passage of brain derived Aβ into the bloodstream (Shibata et al., 2000; Deane et al., 2004a,b).”
BackgroundSink Hypothesis and Therapeutic Strategies for Attenuating Aβ Levels
Zhang, Y., & Lee, D. H. S. (2011) · The Neuroscientist · doi:10.1177/1073858410381532 · Cited by 57
Cerebrospinal Fluid Dynamics and the Pathophysiology of Hydrocephalus: New Concepts
Yamada, S., & Kelly, E. J. (2016) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2016.01.001 · Cited by 67
Self-citationShin, S. J., Nam, Y., Park, Y. H., Kim, M., Lee, E., Jeon, S. G., Bae, B.-S., Seo, J., Shim, S., Kim, J.-S., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.454 · Cited by 62
The Concentration of Soluble Extracellular Amyloid-β Protein in Acute Brain Slices from CRND8 Mice
Waters, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015709 · Cited by 65
Coniferaldehyde attenuates Alzheimer's pathology via activation of Nrf2 and its targets
Dong, Y., Stewart, T., Bai, L., Li, X., Xu, T., Iliff, J. J., Shi, M. Y., Zheng, D., Yuan, L., Wei, T., et al. (2019) · Theranostics · doi:10.7150/thno.36722 · Cited by 63
“Previous works [71, 72] have proposed several mechanisms: blood brain barrier (BBB)-specific efflux, interstitial fluid (ISF) bulk flow and cerebrospinal fluid absorption.”
BackgroundLichtlen, P., & Mohajeri, M. H. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05064.x · Cited by 59
“Nevertheless, macromolecules and peptides can be cleared from the brain to a limited degree by a non-specific bulk flow from brain interstitial fluid and CSF (Shibata et al. 2000).”
BackgroundtPA Deficiency Underlies Neurovascular Coupling Dysfunction by Amyloid-β
Park, L., Zhou, J., Koizumi, K., Wang, G., Anfray, A., Ahn, S. J., Seo, J., Zhou, P., Zhao, L., Paul, S. M., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1140-20.2020 · Cited by 60
“To investigate the effect of the low-density lipoprotein receptorrelated protein 1 (LRP1) inhibitor receptor-associated protein (RAP; Shibata et al., 2000; Deane et al., 2004) on functional hyperemia, this agent (200 nM; Molecular Innovations) was superfused over the somatosensory cortex, and its…”
BackgroundWalker, J. R., Pacoma, R., Watson, J., Ou, W., Alves, J., Mason, D. E., Peters, E. C., Urbina, H. D., Welzel, G., Althage, A., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3407-12.2013 · Cited by 58
Increased amyloid β-peptide (1–40) level in brain of streptozotocin-induced diabetic rats
Liu, Y., Liu, H., Yang, J., Liu, X., Lü, S., Wen, T., Xie, L. Y., & Wang, G. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.03.019 · Cited by 64
Zou, C., Mifflin, L., Hu, Z., Zhang, T., Shan, B., Wang, H., Xing, X., Zhu, H., Adiconis, X., Levin, J. Z., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108447 · Cited by 64
LaRue, B., Hogg, E., Sagare, A. P., Jovanovic, S. S., Maness, L. M., Maurer, C. R., Deane, R., & Zloković, B. V. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.04.026 · Cited by 64
Apolipoprotein E protects cultured pericytes and astrocytes from D-Aβ1–40-mediated cell death
Bruinsma, I. B., Wilhelmus, M. M. M., Kox, M., Veerhuis, R., de Waal, R. M. W., & Verbeek, M. M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.12.039 · Cited by 63
“It has been suggested that high apoE levels may be essential in clearance of Aβ across the blood–brain barrier (BBB) via a member of the LDLR family, probably the LDLR-related protein (LRP-1 protein) (Urmoneit et al., 1997; Shibata et al., 2000; Zlokovic, 2004;Wilhelmus et al., 2005).”
Kandimalla, K. K., Curran, G. L., Holasek, S. S., Gilles, E. J., Wengenack, T. M., & Poduslo, J. F. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081901 · Cited by 63
“Recent reports have suggested that A 40 exhibits bidirectional transport between the peripheral circulation and brain via the BBB (Shibata et al., 2000; Deane et al., 2003).”
BackgroundInfluentialStress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders
Kitamura, Y., & Nomura, Y. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00301-7 · Cited by 59
Vascular and Metabolic Factors in Alzheimer’s Disease and Related Dementias: Introduction
Iadecola, C. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0319-y · Cited by 66
“2015), and (b) by binding vascular transport receptors (LRP1, PICALM) and crossing the vascular wall to reach the circulation (Shibata et al. 2000; Storck et al. 2015; Zhao et al. 2015).”
Yamada, K., & Iwatsubo, T. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05225-z · Cited by 70
“It has also demonstrated that soluble Aβ is actively transported into the bloodstream through transporters pres-ent in the blood-brain barrier (BBB) [19 ].”
BackgroundMohamed, L. A., Qosa, H., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00040 · Cited by 58
Yang, B., Li, S., Chen, Z., Feng, F., He, L., Liu, B., He, T., Wang, X., Chen, R., Chen, Z., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201901550r · Cited by 63
Upregulation of APP endocytosis by neuronal aging drives amyloid-dependent synapse loss
Burrinha, T., Martinsson, I., Gomes, R., Terrasso, A. P., Gouras, G. K., & Almeida, C. G. (2021) · Journal of Cell Science · doi:10.1242/jcs.255752 · Cited by 64
“Dynamin polymerizes around the vesicle neck, cutting it upon GTP hydrolysis (Roux et al., 2006; Shpetner and Vallee, 1992; Tuma and Collins, 1994).”
BackgroundDavis, J., Xu, F., Miao, J., Previti, M. L., Romanov, G. A., Ziegler, K., & Nostrand, W. E. V. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.031 · Cited by 63
In vivo labeling of amyloid with BF-108
Suemoto, T., Okamura, N., Shiomitsu, T., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Kudo, Y., & Sawada, T. (2003) · Neuroscience Research · doi:10.1016/j.neures.2003.09.005 · Cited by 63
Role of the cannabinoid system in the transit of beta-amyloid across the blood–brain barrier
Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.06.004 · Cited by 60
“, 2003), which is a major transporter in the brainto-blood clearance of Aβ across the BBB (Shibata et al., 2000).”
InfluentialLiang, F., Jia, J., Wang, S., Qin, W., & Liu, G. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.06.005 · Cited by 59
Serum biomarkers for Alzheimer's disease: Proteomic discovery
German, D. C., Gurnani, P., Nandi, A., Garner, H. R., Fisher, W. G., Diaz-Arrastia, R. R., O’Suilleabhain, P. E., & Rosenblatt, K. P. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.05.009 · Cited by 57
Dong, H. K., Gim, J., Yeo, S. H., & Kim, H. (2016) · Gene · doi:10.1016/j.gene.2016.10.022 · Cited by 69
Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium
d'Uscio, L. V., He, T., & Katusic, Z. S. (2017) · Physiology · doi:10.1152/physiol.00021.2016 · Cited by 57
Cerebral beta-amyloid angiopathy in aged squirrel monkeys.
Elfenbein, H. A., Rosen, R. F., Stephens, S. L., Switzer, R. C., Smith, Y., Paré, J., Mehta, P. D., Warzok, R., & Walker, L. C. (2007) · PubMed · doi:10.14670/hh-22.155 · Cited by 55
Tanskanen, M., Lindsberg, P. J., Tienari, P. J., Polvikoski, T., Sulkava, R., Verkkoniemi, A., Rastas, S., Paetau, A., & Kiuru‐Enari, S. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00652.x · Cited by 55
RETRACTED: Gene regulation by antisense transcription: A focus on neurological and cancer diseases
Najafi, S., Tan, S. C., Raee, P., Rahmati, Y., Asemani, Y., Lee, E. H. C., Hushmandi, K., Zarrabi, A., Aref, A. R., Ashrafizadeh, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112265 · Cited by 57
RetractedReliable Measurements of theβ-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
Pesini, P., Pérez‐Grijalba, V., Monleón, I., Boada, M., Tárraga, L., Martínez‐Lage, P., José, I. S., & Sarasa, M. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/604141 · Cited by 65
Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus
Jeppsson, A., Hölttä, M., Zetterberg, H., Blennow, K., Wikkelsø, C., & Tullberg, M. (2016) · Fluids and Barriers of the CNS · doi:10.1186/s12987-016-0037-y · Cited by 57
“Recent insights into the glymphatic system, has provided possibilities for a new route for clearance of excess fluid and interstitial metabolites, including Aβ, from the brain parenchyma [24, 25], together with clearance of Aβ across the blood– brain barrier (BBB) via the LRP-1 receptor [26].”
Supraphysiologic-dose anabolic–androgenic steroid use: A risk factor for dementia?
Kaufman, M. J., Kanayama, G., Hudson, J. I., & Pope, H. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.014 · Cited by 65
Inflammation: major denominator of obesity, Type 2 diabetes and Alzheimer’s disease-like pathology?
Kacířová, M., Zmeškalová, A., Kořínková, L., Železná, B., Kuneš, J., & Maletínská, L. (2020) · Clinical Science · doi:10.1042/cs20191313 · Cited by 53
Targeting Alzheimer’s disease with multimodal polypeptide-based nanoconjugates
Duro‐Castaño, A., Borrás, C., Herranz‐Pérez, V., Blanco-Gandía, M. C., Conejos‐Sánchez, I., Armiñán, A., Mas‐Bargues, C., Inglés, M., Miñarro, J., Rodríguez‐Arias, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf9180 · Cited by 58
Apolipoprotein E Genotype Regulates Amyloid-β Cytotoxicity
Wilhelmus, M. M. M., Otte-Höller, I., Davis, J., Van Nostrand, W. E., de Waal, R. M. W., & Verbeek, M. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4213-04.2005 · Cited by 53
“ApoE, which is also a ligand for LRP-1, may facilitate the clearance of A from the brain, because clearance was significantly reduced in ApoE / mice (Shibata et al., 2000).”
BackgroundAquaporin-4 and Cognitive Disorders
Wang, Y., Huang, C., Guo, Q., & Chu, H. (2022) · Aging and disease · doi:10.14336/ad.2021.0731 · Cited by 55
“Previously, it was believed that the clearance of Aβ mainly depended on the active transport of the BBB due to the lack of conventional lymphoid circulation in the brain [14].”
BackgroundDeMattos, R. B. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:255 · Cited by 55
“Studies first performed by Zlokovic and colleagues showed that exogenously administered 125I-labeled human Aβ to nontransgenic animals could be transported bidirectionally from plasma to CNS and conversely from CNS to plasma (Zlokovic et al., 1993, 1994; Ghersi-Egea et al., 1996; Shibata et al., 2000).”
BackgroundInfluentialNetwork-driven anomalous transport is a fundamental component of brain microvascular dysfunction
Goirand, F., Borgne, T. L., & Lorthois, S. (2021) · Nature Communications · doi:10.1038/s41467-021-27534-8 · Cited by 60
Receptor-associated Protein Interacts with Amyloid-β Peptide and Promotes Its Cellular Uptake
Kanekiyo, T., & Bu, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.015032 · Cited by 44
The role of neurovascular unit damage in the occurrence and development of Alzheimer’s disease
Liu, X., Hou, D., Lin, F., Luo, J., Xie, J., Wang, Y., & Tian, Y. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0056 · Cited by 60
Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level
Al Rihani, S. B., Darakjian, L. I., Deodhar, M., Dow, P., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073742 · Cited by 51
Alterations in β-amyloid production and deposition in brain regions of two transgenic models
Lehman, E. J. H., Kulnane, L. S., & Lamb, B. T. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00153-7 · Cited by 55
“In addition, low density lipoprotein receptor-related protein, which works with ,2-macroglobulin to clear soluble A [17,24,27,28] is most abundantly expressed in the cortex and hippocampus [22].”
BackgroundAntibody Therapeutics Targeting Aβ and Tau
Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 50
Self-citationLi, W., Chen, Q., Peng, C., Yang, D., Liu, S., Lv, Y., Jiang, L., Xu, S., & Li-hua, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010403 · Cited by 59
“Studies [143] have Brain A β is removed through endocytosis mediated by the LRP1 receptor, which facilitates the clearance of brain-derived A β [137,138]. demonstrated that the RAGE-TXNIP axis facilitates the movement of A β from the cell A β that is bound to RAGE is internalized across the…”
Rózga, M., & Bal, W. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900358j · Cited by 58
Hao, W., Liu, Y., Liu, S., Walter, S., Grimm, M. O., Kiliaan, A. J., Penke, B., Hartmann, T., Rübe, C. E., Menger, M. D., et al. (2011) · Brain · doi:10.1093/brain/awq325 · Cited by 56
“…control animals, Ab precursor protein transgenic mice with MyD88-deficient bone marrow reconstruction showed changes neither in plasma Ab levels nor in cerebral expression of RAGE and LRP1, involved in transport of Ab across the blood–brain barrier (Shibata et al., 2000; Deane et al., 2003, 2004).”
BackgroundMethodKoudinov, A. R., Berezov, T. T., & Koudinova, N. V. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02263-7 · Cited by 57
Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease
Wisniewski, T., & Frangione, B. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00102.x · Cited by 54
“Accumulation of Aβ in AD brains is associated with increased production and/or impaired clearance which have been both observed with advancing age and in sporadic AD (63).”
BackgroundSelf-citationTreating Alzheimer’s disease using nanoparticle-mediated drug delivery strategies/systems
Roghani, A. K., Garcia, R. I., Roghani, A., Reddy, A. P., Khemka, S., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102291 · Cited by 59
A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier
Bachmeier, C., Paris, D., Beaulieu-Abdelahad, D., Mouzon, B., Mullan, M., & Crawford, F. (2013) · Neurodegenerative Diseases · doi:10.1159/000337231 · Cited by 48
Huang, Y. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390924 · Cited by 48
Environmental factors in the development and progression of late-onset Alzheimer’s disease
Wainaina, M. N., Chen, Z., & Zhong, C. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1425-9 · Cited by 59
“[121] Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al.”
BackgroundAquaporin-4 and Alzheimer’s Disease
Yang, C., Huang, X., Huang, X., Mai, H., Li, J., Jiang, T., Wang, X., & Lü, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150949 · Cited by 59
“Previous animal studies have confirmed that active transport across BBB is probably the most prominent pathway in the clearance of extracellular A (cid:2) , which showed that 73.8% A (cid:2) 40 is cleared by BBB, with only 10.7% A (cid:2) 40 being cleared by ISF bulk flow [46].”
InfluentialDoes sleep disturbance affect the amyloid clearance mechanisms in A lzheimer's disease?
Yuluğ, B., Hanoğlu, L., & Kılıç, E. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12539 · Cited by 53
“In this context, experimental studies have already shown the role of Aqp4-dependent trans-astrocytic ISF bulk flow in the clearance of Aβ through the glymphatic system.(24,37,38) These results were confirmed with subsequent studies using Aqp4-knockout mice showing reduced A 40 clearance that resulted in Aβ deposition…”
Result
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






